Hemab Therapeutics Holdings, Inc. · NASDAQ:COAG

Sofinnova Crossover II SLP reported a 5.40% stake in Hemab Therapeutics Holdings, Inc. (Schedule 13G)

Event Jun 30, 2026 · Filed Aug 5, 2026

Sofinnova Crossover II SLP reported a 5.40% stake in Hemab Therapeutics Holdings, Inc., 2,511,212 shares, as a passive investor on Jun 30, 2026. Filed Aug 5, 2026 (Schedule 13G).

Stake
5.40%
Shares
2,511,212
Intent
Passive
What changed
Crossed above 5%
Filed together
7 holders

The filing in full

HolderStakeShares
Sofinnova Crossover II SLP5.40%2,511,212
Sofinnova Partners SAS, a French corporation5.40%2,511,212
Antoine Papiernik5.40%2,511,212
Cedric Moreau5.40%2,511,212
Kinam Hong5.40%2,511,212
Joseph Anderson5.40%2,511,212
David Evans5.40%2,511,212

Source

View original at SEC

Related